What is Endothelix?
Endothelix operates at the intersection of cardiovascular diagnostics and office-based clinical efficiency. The company is the developer of VENDYS, an FDA-cleared, automated medical device engineered to measure vascular reactivity and endothelial function. By providing a noninvasive, accessible platform for physicians, Endothelix enables the direct assessment of vascular health and the stratification of cardiovascular event risk. This technology addresses a critical gap in preventative cardiology, allowing healthcare providers to integrate sophisticated physiological testing directly into routine patient consultations, thereby improving diagnostic accuracy and long-term patient outcomes.
How much funding has Endothelix raised?
Endothelix has raised a total of $100K across 1 funding round:
Debt
$100K
Debt (2021): $100K with participation from PPP
Key Investors in Endothelix
PPP
Public-Private Partnership
What's next for Endothelix?
With the successful closure of this late-stage financing, Endothelix is poised to scale its commercial operations and expand the footprint of its VENDYS platform. The strategic focus will likely shift toward broader market penetration, targeting healthcare institutions that prioritize early intervention and data-driven cardiovascular management. As the company matures, the integration of its vascular reactivity data into broader electronic health record systems could serve as a key growth catalyst, further cementing its role as an essential partner in modern clinical practice. The firm remains focused on scaling its infrastructure to meet the rising demand for high-fidelity, noninvasive diagnostic tools in the global healthcare market.
See full Endothelix company page
